文献速递湿疹皮炎与荨麻疹

靶向组胺4受体治疗胆碱能性荨麻疹:izuforant二期a随机双盲安慰剂对照交叉试验

Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial.
PubMed 文献 · Br J Dermatol · 2024-01-01

主要终点及多数预设探索性终点未达到,仅患者整体严重度评估(PGA-S)较安慰剂显著改善(P=0.02)。izuforant耐受性良好,不良事件均为轻度。

要点

  • izuforant 100 mg每日两次未显著改善胆碱能性荨麻疹主要终点。
  • 仅PGA-S较安慰剂显著改善(P=0.02),其余终点无显著差异。
  • izuforant耐受性良好,不良事件均为轻度,无治疗相关严重不良事件。

核心结论

  • 靶向H4R的izuforant耐受性良好,但未在主要终点及除PGA-S外的所有预设探索性终点中较安慰剂显示显著改善。
  • 这是首个探索H4R作为荨麻疹治疗靶点的研究。

研究设计与样本

  • 二期a随机双盲安慰剂对照多中心交叉试验(EUCTR2020-004961-38-DE;NCT04853992)。
  • 纳入对至少1个标准剂量H1抗组胺药应答不足的胆碱能性荨麻疹患者,随机接受izuforant 100 mg每日两次或安慰剂。
  • 主要终点为荨麻疹活动度评分(UAS)自基线的变化。

主要发现

  • 主要终点及多数预设探索性终点未达到。
  • PGA-S在izuforant组较安慰剂组显著改善(P=0.02)。
  • 生活质量及组胺皮肤点刺试验等其他终点呈非显著改善。
  • izuforant相关不良事件均为轻度,最常见为恶心(3例)和上腹痛(2例),在izuforant组较安慰剂组(各1例)更常见。
  • 无治疗相关严重不良事件,无izuforant组患者因不良事件退出研究;izuforant未导致H4R下调。

关键数值与推荐

  • 主要终点:UAS自基线变化,未达到。
  • PGA-S:izuforant vs 安慰剂 P=0.02,显著改善。
  • 其他预设探索性终点(含CholU活动度评分7天、荨麻疹控制试验、医生整体评估、激发试验、DLQI、CholU-QoL):无显著改善。

临床怎么用

  • 当前证据不支持izuforant 100 mg每日两次用于对H1抗组胺药应答不足的胆碱能性荨麻疹的常规治疗。
  • H4R作为荨麻疹治疗靶点仍需进一步研究验证。

局限性

  • 为二期a探索性研究,主要终点及多数探索性终点未达到。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cholinergic urticaria (CholU) is a common subtype of chronic inducible urticaria, where signs and symptoms (e.g. pruritic wheals and angioedema) are triggered by sweating due to physical exercise, passive warming and by other sweat-inducing situations. While guidelines recommend treatment with second-generation H1 antihistamines, approximately 90% of patients report uncontrolled disease. Targeting the histamine 4 receptor (H4R) has shown promise in preclinical/clinical studies of allergic/inflammatory diseases. Izuforant (LEO 152020) is a selective oral H4R antagonist with expected dual antipruritic and anti-inflammatory effects. OBJECTIVES: To assess the effects of izuforant in adults with CholU, a common type of chronic urticaria driven by histamine and characterized by high skin levels of H4R expression. METHODS: This was a phase IIa randomized double-blind placebo-controlled multicentre crossover trial where patients with CholU with an inadequate response to ≥ 1 standard dose of H1 antihistamine received izuforant 100 mg twice daily or placebo (EUCTR2020-004961-38-DE; NCT04853992). The primary endpoint was change from baseline in Urticaria Activity Score. Exploratory endpoints included CholU activity score over 7 days, urticaria control test, Physician Global Assessment, patient global assessment of severity (PGA-S), provocation tests, Dermatology Life Quality Index and CholU quality of life (CholU-QoL). Pharmacokinetic and pharmacodynamic parameters, and serum biomarkers were assessed, as well as safety and tolerability. RESULTS: Nineteen patients were randomized and included in the full analysis set; 18 completed treatment [mean (SD) age 29.5 (9.8) years; mean (SD) CholU duration 8.0 (6.3) years]. The primary and most of prespecified exploratory endpoints were not met; there were significant improvements in PGA-S for izuforant vs. placebo (P = 0.02), and nonsignificant improvements for other endpoints in quality of life and histamine skin prick test. All adverse events (AEs) experienced with izuforant were considered mild. The most frequently reported (> 1 patient) were nausea (three patients) and upper abdominal pain (two patients), occurring more frequently with izuforant vs. placebo (one patient each). There were no treatment-related serious AEs and no patient receiving izuforant discontinued the study. Treatment with izuforant did not cause downregulation of H4R. CONCLUSIONS: This is the first study to explore the role of H4R as a therapeutic target in urticaria. Targeting H4R with izuforant was well tolerated but did not demonstrate significant improvements vs. placebo in the primary endpoint and all but one prespecified exploratory endpoint in CholU. Cholinergic urticaria (CholU) is a common subtype of an inflammatory skin condition called chronic inducible urticaria, where signs and symptoms (e.g. hives and swelling in the skin) are triggered by sweating caused by physical exercise, passive warming and other sweat-inducing situations. While guidelines recommend treatment with second-generation H1 antihistamines (a type of medication), approximately 90% of people with the condition report that these medications do not control the disease. Targeting the histamine 4 receptor (H4R) has shown promise in studies of allergic/inflammatory diseases. CholU is driven by histamine (a chemical released in the body) and characterized by high skin levels of H4R. Izuforant is a medication that may reduce itch and inflammation. In our study, which was carried out across multiple sites in Germany, we assessed the effects of izuforant 100 mg in 18 patients with CholU using a range of measures covering symptom control, disease severity, provocation response and quality of life. The primary endpoint (the main result measured at the end of the study to see if the treatment worked) was change from baseline in the post-provocation Urticaria Activity Score, where areas of skin were provoked and the time until common symptoms of CholU appeared (sweating and whealing (hives)) was measured. Overall, the primary endpoint and most of the exploratory endpoints were not met. There were significant improvements in patients’ global assessment for izuforant versus placebo. This was the first study to explore the role of H4R as a therapeutic target in urticaria. Our findings suggest that targeting H4R with izuforant was well tolerated but did not demonstrate significant improvements versus placebo in the primary endpoint, and all but one prespecified exploratory endpoint in CholU.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Grekowitz E, Metz M, Altrichter S, et al. Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial. Br J Dermatol. 2024. PMID: 38308655. doi:10.1093/bjd/ljae038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。